Exo Therapeutics has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. Combining this approach with DNA-encoded libraries, the company is generating more potent drugs with higher specificity to the targeted substrate. Exo has identified a series of high-value target opportunities within oncology and is focusing its efforts on validation of reprogramming enzymes using exo-site function-selective inhibitors.